European Society of Clinical Microbiology and Infectious Diseases

Sight Sciences Reports Third Quarter 2023 Financial Results and Withdraws Guidance for Full Year 2023

Retrieved on: 
Tuesday, November 7, 2023
Telecanthus, EEG microstates, Trial of the century, OMNI, LCD, WPS, Ophthalmology, Medicare, MIGS, Macs, Congress, IOP, Publication, GAAP, Nature, Environment, News, Growth, Cataract, Clinical trial, Surgeon, American Academy, Webcast, London, Refraction, European Society of Clinical Microbiology and Infectious Diseases, Centers for Medicare & Medicaid Services, Patient, GEMINI, Pharmaceutical industry, Video game, Ciclosporin

Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.

Key Points: 
  • Generated third quarter 2023 total revenue of $20.0 million, an increase of 7% compared to the same period in the prior year.
  • Achieved total gross margin of 86.6% in the third quarter of 2023 compared to 84.3% in the same period in the prior year.
  • On October 26, 2023, WPS Government Health Administrators (“WPS”), a Medicare Administrative Contractor (“MAC”), published an LCD with an effective date of December 24, 2023.
  • Sight Sciences' management team will host a conference call today, November 7, 2023, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, November 3, 2023
Gene editing, International Symposium on Endovascular Therapy, FDA, Research, Food, Rhodopsin, Human, Congress, Fragile X syndrome, G&A, Liver, CFTR, Chromosomal translocation, Regulation of tobacco by the U.S. Food and Drug Administration, Cell, Initial, R, Society, ASH, RHO, Tissue, Lung, Cystic fibrosis, Prime editing, Gene, Composition, Abstract, LNP, Eye, Safety, European Society of Clinical Microbiology and Infectious Diseases, Investment, CGD, Patient, Retina, NHP, Patent, D, Vaccine, Pharmaceutical industry, Fine chemical, Beef cattle, Video game, Cryptocurrency, IND

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.

Key Points: 
  • 11,795,452 --
    CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the third quarter ended September 30, 2023.
  • Together, these encouraging results mark meaningful progress toward the clinic and support our strategy of simultaneously advancing multiple programs forward.
  • In August 2023, Prime Medicine received Rare Pediatric Drug designation (RPDD) from the U.S. Food and Drug Administration (FDA) for PM359.
  • Year-to-date, Prime Medicine continues to make significant progress, executing against key initiatives to drive its Prime Editing platform forward.

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, November 2, 2023
SLE, Patient, FDA, EBMT, Medical Affairs Bureau, Trial of the century, Research, CAR, Multiple myeloma, Financial result, CD19, European Medicines Agency, Conference, UCL, Society, Program management, ASH, Senior, MHRA, MRD, Canadian Aviation Regulations, EMA, Nucleus, Autoimmune disease, Hand, European Society of Clinical Microbiology and Infectious Diseases, Conference call, Therapy, BCMA, Blackstone, ALL, BLA, Nature Medicine, GD2, Construction, Pharmaceutical industry, Nursing, Vaccine, Payment card, Cryptocurrency, EU, Blood

Patients continue to be enrolled and initial data will be presented at ASH in December 2023.

Key Points: 
  • Patients continue to be enrolled and initial data will be presented at ASH in December 2023.
  • Financial Results for the Third Quarter Ended September 30, 2023
    Cash and cash equivalents at September 30, 2023, totaled $256.4 million, as compared to $382.4 million at December 31, 2022.
  • Autolus estimates that its current cash and cash equivalents on hand and anticipated future milestone payment from Blackstone will extend the Company’s cash runway into 2025.
  • Unaudited Financial Results for the Third Quarter Ended September 30, 2023

Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Health, Oncology, ASPS, ESMO, Medicare, EBITDA, European Society for Medical Oncology, Net, GAAP, Acquisition, Helmy Eltoukhy, Cancer, Lung, Growth, PEGASUS, GH, Marketing, Partnership, Webcast, MRD, Depreciation, European Society of Clinical Microbiology and Infectious Diseases, Forecasting, Video game, Medical imaging, Pharmaceutical industry, Bank, Insurance, Shield

Precision oncology gross margin was 60% in the third quarter of 2023, as compared to 61% in the prior year period.

Key Points: 
  • Precision oncology gross margin was 60% in the third quarter of 2023, as compared to 61% in the prior year period.
  • Operating expenses were $199.0 million for the third quarter of 2023, as compared to $221.5 million for the corresponding prior year period.
  • Guardant Health now expects full year 2023 revenue to be in the range of $553 to $556 million, representing growth of 23% to 24% compared to full year 2022.
  • Guardant Health will host a conference call to discuss the third quarter and full year 2023 financial results after market close on Monday, November 6, 2023 at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

Global Platform Study Presents Results to Guide Care of Severely Ill Patients With COVID-19 Using Routinely Available Drugs – Simvastatin and Vitamin C

Retrieved on: 
Wednesday, October 25, 2023
Science, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Hospitals, Clinical Trials, WHO, Urinary tract infection, Survival, FRCP, Patient, Vitamin C, Simvastatin, Royal Victoria Hospital, Montreal, Bronchopneumonia, MPH, Global Coalition Against Pneumonia, Oregon Health & Science University, University, Respiratory tract infection, JAMA, Professor, Vitamin, Multimedia, Queen's University Belfast, University of Pittsburgh School of Medicine, Learning, Critical Care Medicine (journal), COVID, Clinical trial, Intensive care unit, Hospital, NEJM, Probability, Pittsburgh, European Society of Clinical Microbiology and Infectious Diseases, Wilfrid Sellars, SUNY Downstate Health Sciences University, Hospice and palliative medicine, Intensive care medicine, Royal Victoria Hospital, UPMC, Consultant, Ohio State University Wexner Medical Center, Pharmaceutical industry, Dietary supplement, MD

Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.

Key Points: 
  • Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.
  • Through harmonizing two clinical trials – REMAP-CAP and LOVIT-COVID – over 2500 patients in 20 countries took part, including both critically ill and non-critically ill patients with COVID-19 in hospital.
  • It was shown that high dose vitamin C did not improve outcomes for patients.
  • Intravenous Vitamin C for Patients Hospitalized with COVID-19: Two Harmonized Randomized Clinical Trials.

Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA

Retrieved on: 
Wednesday, October 18, 2023
Q&A, American Institute, International Conference on Bioinformatics, Haemophilia, Therapy, RNA, Biotechnology, LNP, Congress, Liver, IL-6, Cytokine, Conference, American Institute of Chemical Engineers, VIII, RES, Mouse, European Society of Gene and Cell Therapy, Tissue, Cell, Gene, Webcast, Messenger, ESGCT, Generation, European Society of Clinical Microbiology and Infectious Diseases, Investment, Patient, NHP, DNA, Mobile phone, Vaccine, Moderna

CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company developing genetic medicines for people living with rare and prevalent diseases, today announced the development of a proprietary, novel DNA called immune-quiet DNA (iqDNA). iqDNA is an optimized variant of the company’s closed-ended DNA (ceDNA) that upon systemic administration with Generation Bio’s lipid nanoparticle (LNP) delivery has shown cytokine levels and tolerability comparable to chemically modified messenger RNA (mRNA) in mice and non-human primates (NHPs).

Key Points: 
  • Generation Bio’s non-viral genetic medicine platform aims to advance durable, redosable, and titratable therapies to reach potentially hundreds of millions of patients worldwide.
  • The company has made deep investments in its three proprietary platform technologies, comprising novel DNA cargos, rapid enzymatic synthesis (RES) manufacturing, and cell-targeted LNP (ctLNP) delivery.
  • The presentation will cover the development and progress of Generation Bio’s ctLNP platform, including its stealth and targeting delivery system.
  • Registration information for the webcast can be found on the Events page of Generation Bio’s investor website.

12th IAU Annual Conference in 2023: London Witnesses Outstanding Gathering in the Field of Urolithiasis

Retrieved on: 
Wednesday, October 11, 2023
Conference, Quality of life, EULIS, WCE, Book, Urology, Patient, University College London Hospitals NHS Foundation Trust, BPS Barbara Wilson Lifetime Achievement Award, Guideline, Kidney, UCLH, Surgeon, European Society of Clinical Microbiology and Infectious Diseases, International Alliance of Research Universities, Minimally invasive procedure, SIU, Research, Pharmaceutical industry, Endoscopy, Kidney stone disease, IAU

From October 4th to 6th 2023, the 12th Annual Conference of IAU was grandly held in London, United Kingdom.

Key Points: 
  • From October 4th to 6th 2023, the 12th Annual Conference of IAU was grandly held in London, United Kingdom.
  • In addition to academic communication, the IAU Annual Conference presented multiple awards to recognize experts who have made outstanding contributions in the field of urolithiasis.
  • The first-ever IAU Annual Conference held in London highlighted the significant progress achieved in international collaboration in this field.
  • The 2023 IAU Annual Conference in London was a historic event in the field of urolithiasis.

Atamyo Therapeutics Announces participation in Conferences and Key Scientific Communications on its LGMD programs

Retrieved on: 
Friday, September 29, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Muscular dystrophy, Natural history, International, Gene, C2, Rentschler, Part, ESGCT, Facial muscles, Neuromuscular disease, Diplomatic mission, Circulatory system, Rigshospitalet, Cell, Public, Oral, European Society of Clinical Microbiology and Infectious Diseases, Therapy, Conference, Pharmaceutical industry, Oyster farming, Nightclub, Rare-earth element, MD

Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation to forthcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).

Key Points: 
  • Atamyo Therapeutics , a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular disease, today announced its participation to forthcoming conferences and scientific communications on its programs targeting limb-girdle muscular dystrophies (LGMDs).
  • Stephane Degove, Atamyo CEO, will provide a corporate overview at two forthcoming conferences in October:
    Chardan's 7th Annual Genetic Medicines Conference, held in New York City:
    - Presentation on October 2, at 10:30 AM, in the Embassy room
    Cell & Gene Meeting on the Mesa, held in Carlsbad, CA, on October 10-12, 2023:
    - Presentation on October 10, at 5:15pm, at the Rentschler ATMP Ballroom
    Two upcoming communications at the 28th Annual Congress of the World Muscle Society (3-7 October 2023 in Charleston, SC)
    • Oral Presentation by A. Brureau (Genethon), at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
    • Poster Board Number 282 at Ballroom C, on October 4, 2023, 17h15-18h15
    Natural history of limb girdle muscular dystrophy R9: one-year follow-up of a European cohort
    • Oral Presentation by J. Vissing (Copenhagen Neuromuscular Center, Rigshospitale) at Ballroom C2 on October 4, 2023 from 18h15 to 18h45
    • Poster Board Number 283 at Ballroom C, on October 4, 2023, 17h15-18h15
    Two communications describing Atamyo’s LGMD programs will be presented at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) that will take place on October 24-27, 2023 in Brussel (Belgium):
    • Oral presentation by Nicolai Preisler, MD, Rigshospitalet, Copenhagen, during the Cardiovascular and muscular diseases session, on Friday October 27, 11h30-13h00 – Le BEL, Tour & Taxis
    Oral presentation on Atamyo’s LGMD-R9 program at the 2023 International Limb-Girdle Muscular Dystrophy Conference (28-29 October 2023, Washington DC)
    • Oral presentation by John Vissing, MD, Rigshospitalet, Copenhagen, during the Clinical Trials Updates (Part 1) Session, on October 29, 11h00am-12h10pm – Constitution Ballroom, Grand Hyatt

SourceAmerica Employment Inclusion Survey Reveals Nationwide Desire for More Employer Support for People with Disabilities

Retrieved on: 
Monday, September 18, 2023
Private sector, Employment, Defense, Public opinion, Disability, Workplace, SourceAmerica, Opinion, Javits–Wagner–O'Day Act, ESOMAR, Market Research Society, Human, OnePoll, Veteran, Marketing, Government, American Association for Public Opinion Research, Congress, National Disability Employment Awareness Month, U.S. Department of Defense Strategy for Operating in Cyberspace, European Society of Clinical Microbiology and Infectious Diseases, Research, AAPOR, Nursing, Tutoring, Insurance

VIENNA, Va., Sept. 18, 2023 /PRNewswire/ -- SourceAmerica®, an AbilityOne® authorized enterprise committed to increasing employment opportunities for people with disabilities, today announced results of a recent national survey that revealed 93% of respondents desire the private sector and government to take a more active role in supporting employment opportunities for people with disabilities.

Key Points: 
  • "The survey results strengthen our resolve to help create access to jobs for people with disabilities.
  • In recognition of National Disability Employment Awareness Month (NDEAM) this October, SourceAmerica commissioned this survey which was independently conducted by market research company OnePoll between July 14 and July 21, 2023.
  • "The survey results highlight the need for better access to employment opportunities for people with disabilities.
  • The AbilityOne Program is among the nation's largest sources of employment for people who are blind or have significant disabilities.

Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Retrieved on: 
Monday, September 11, 2023
Vaccine, Interim, Senior, Virulence, Bronchopneumonia, American Society for Microbiology, European Society of Clinical Microbiology and Infectious Diseases, Infection, End organ damage, MD, Disease, Mortality, Congress, Society, Pharmaceutical industry

WOODCLIFF LAKE, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its abstract describing the global in-progress Phase 2 study of CAL02, a first-in-class, broad-spectrum, anti-virulence agent under development as an adjunct to antibiotic therapy for the treatment of severe community-acquired bacterial pneumonia (“SCABP”), has been selected for a poster presentation at the conference co-sponsored by the American Society for Microbiology (“ASM”) and the European Society for Clinical Microbiology and Infectious Diseases (“ESCMID”). This prestigious, multidisciplinary meeting is focused on the challenges, opportunities, and current requirements for antimicrobial drug development to address antimicrobial resistance. The conference is scheduled to take place September 19-22, 2023, in Boston, Massachusetts.

Key Points: 
  • This prestigious, multidisciplinary meeting is focused on the challenges, opportunities, and current requirements for antimicrobial drug development to address antimicrobial resistance.
  • The conference is scheduled to take place September 19-22, 2023, in Boston, Massachusetts.
  • “We are pleased to have the opportunity to present additional details of the CAL02 study in progress to our esteemed colleagues,” stated Valentin Curt, MD, Senior Vice President, Clinical Drug Development and Interim Chief Medical Officer at Eagle Pharmaceuticals.
  • “Inclusion at this scientific congress supports the significance of the potential clinical value of CAL02 to address a large, unmet medical need.